phthalmic Fluid of OBioFirst obtains Canadian patent. (August 07, 2014)

BioFirst has announced that they have obtained patent approval in Canada for their primary product “Ophthalmic Fluid”. With its previous patent approvals by Australia, the product has received patents from two countries so far. According to the reports from National Health Insurance Administration, in Taiwan, the average number of ocular surgery is 150 thousand per year, including 100 thousand of cataract operations, costing about two to three hundred million NTD. Not to mention that the global market could be even bigger. BioFirst points out that specific formulated fluid are widely used during various eye surgeries in order to speed up the postoperative recovery. And there is only one single product available in the current market. The new “ocular irrigating solutions” developed by BioFirst has earned the global exclusive license by National Health Research Institutes, and is applicable to various kind of eye surgery. The unique formula enhances the protection to ophthalmic tissues, speed up the recovery after the operation, and also lowers the risk of corneal edema and contraction. Even if there may be postoperative residual, the unique formula will not do harm to the patients’ eyesight. BioFirst further pointed out that “Ophthalmic Fluid” is invented by adding new formula into existing products that have already been approved, which has potential to proceed with Phase III clinical trial directly, and may significantly reduce the time from development to launch. They expected to conduct the phase III clinical trial by 2016, and launching “Ophthalmic Fluid” in 2018.